Effects of NFKB1 and NFKBIA Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathological Features

Affordable Access

Publisher Website

Effects of NFKB1 and NFKBIA Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathological Features

Authors
Publisher
Public Library of Science
Volume
8
Issue
2
Identifiers
DOI: 10.1371/journal.pone.0056130
Keywords
  • Oncology
  • Biology
  • Computational Biology
  • Medicine
  • Genetics
  • Epidemiology
  • Evolutionary Biology
  • Population Genetics
  • Research Article
  • Hepatocellular Carcinoma
  • Gastrointestinal Tumors
  • Genetic Polymorphism
  • Population Biology
  • Gastroenterology And Hepatology
  • Gastrointestinal Cancers
  • Basic Cancer Research
  • Cancers And Neoplasms
  • Cancer Risk Factors
  • Genetic Causes Of Cancer

Abstract

Background Constitutive activation of nuclear factor (NF)-κB is frequently observed in hepatocellular carcinoma (HCC). The current study examined associations of polymorphisms within promoter regions of NFKB1 encoding NF-κB1 and NFKBIA encoding IκBα with the susceptibility of developing HCC and clinicopathological characteristics of the tumors. Methodology and Principal Findings Genetic polymorphisms of NFKB1 and NFKBIA were analyzed by a real-time polymerase chain reaction (PCR) in 135 HCC patients and 520 healthy controls. The genotypic frequency of the NFKB1 -94 Ins polymorphism in HCC patients was significantly higher than that of the controls (adjusted odds ratio (AOR) = 2.23; 95% confidence interval (CI) 1.32∼3.77). No statistical significance was observed for the distribution frequency of the NFKBIA −-519 C/T, -826 C/T, or -881 A/G genotype and haplotype polymorphisms between HCC patients and controls. Furthermore, female HCC patients carrying the NFKB1 -94 Ins polymorphism were associated with lower clinical stages and smaller tumor sizes. Conclusions Our results indicate that the NFKB1 -94 Ins promoter polymorphism increased the risk of HCC, and may be applied as a predictive factor for the clinical stage and tumor size in female HCC patients.

There are no comments yet on this publication. Be the first to share your thoughts.